POROUS POLYMER MICROSPHERES FOR PREVENTING OR TREATING SOFT TISSUE DISEASES AND METHOD FOR MANUFACTURING THE SAME

• US 20190314288A1
• Filed: 05/04/2017
• Published: 10/17/2019
• Est. Priority Date: 08/12/2016
• Status: Abandoned Application

• Current Assignee: Korea University Research and Business Foundation, Ortho Heal Co., Ltd.
• Original Assignee: Korea University Research and Business Foundation
• Inventors: SONG, Hae-Ryong, LEE, Jae Young, KIM, Sungeun, KIM, Hak Jun, YUN, Young-Pil
• Application Number:
  US15/736,084
• Publication Number:
  US 20190314288A1
• Time in Patent Office: Days
• CPC Class Codes: A61K 31/12 Ketones
• CPC Class Codes: A61K 31/167 having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• CPC Class Codes: A61K 31/192 having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid cannabinoids A61K31/658
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61K 9/10 Dispersions; Emulsions A61K9/06 takes precedence; composition of dispersions, emulsions A61K47/00
• CPC Class Codes: A61K 9/1635 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: A61K 9/5026 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: A61K 9/5031 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
• CPC Class Codes: A61L 27/44 having a macromolecular matrix
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 27/56 Porous materials, e.g. foams or sponges
• CPC Class Codes: A61L 27/58 Materials at least partially resorbable by the body
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

Disclosed are porous polymer microspheres for preventing or treating soft tissue diseases including a biodegradable polymer scaffold having a three-dimensional network structure in which pores having a size of 5 to 100 μm are connected to one another, and a drug for treating soft tissue diseases incorporated in the network structure of the biodegradable polymer scaffold.

Claims

1. Porous polymer microspheres for preventing or treating soft tissue diseases comprising:

a biodegradable polymer scaffold having a three-dimensional network structure in which pores having a size of 5 to 100 μ

m are connected to one another; and

a drug for treating soft tissue diseases incorporated in the network structure of the biodegradable polymer scaffold.

2. The porous polymer microspheres according to claim 1, wherein the drug is incorporated in an amount of 2 to 30 parts by weight with respect to 10 parts by weight of the biocompatible polymer.

3. The porous polymer microspheres according to claim 1, wherein the porous polymer microspheres have a porosity of 10 to 90% and a particle size of 200 to 1,000 μ

m.

4. The porous polymer microspheres according to claim 1, wherein the porous polymer microspheres have a porosity of 60 to 90%, a pore size of 10 to 40 μ

m and a particle size of 200 to 500 μ

m.

5. The porous polymer microspheres according to claim 1, wherein the drug for treating soft tissue diseases is selected from transforming growth factor (TGF), platelet derived growth factor (PDGF), basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), insulin like growth factor (IGF), bone morphogenetic protein-7 (BMP-7), anti-inflammatory peptide, aspirin, mefenamic acid, diclofenac sodium, indomethacin, naproxen, acetaminophen, ketoprofen, loxoprofen, piroxicam, ibuprofen, simvastatin, atorvastatin, fluvastatin, lovastatin, copper-peptide, prostaglandin, tramadol, celecoxib, glucosamine, chondroitin, diacerein, methotrexate, cyclosporine, an Janus Kinase 3 inhibitor (JAK-inhibitor), rituximab, tocilizumab, salazosulfapyridine (SASP), bucillamine, leflunomide, infliximab, etanercept, adalimumab, prednisolone, antiflammin 2, curcumin, sulfasalazine, lactoferrin, kartogenin, ibuprofen or a mixture thereof.

6. The porous polymer microspheres according to claim 1, wherein the biocompatible polymer is selected from the group consisting of:

any one selected from polyglycolic acid (PGA), polylactic acid (PLA), poly(lactide-co-glycolide) (PLGA), polycaprolactone (PCL), polyamino acid, polylactide, polyphosphazine, polyiminocarbonate, polyphosphoester, polyanhydride, polyorthoester, polyhydroxyvalerate, polyhydroxybutyrate, hyaluronic acid, cellulose, heparin, collagen, alginate and chitosan;

polymers blended with two or more thereof; and

copolymers of two or more thereof.

7. The porous polymer microspheres according to claim 1, wherein the soft tissue disease is selected from Achilles tendinitis, rotator cuff tendinitis, patellar tendinitis, sprains, ligamentitis, degenerative osteoarthritis and inflammatory arthritis.

8. The porous polymer microspheres according to claim 1, wherein the porous polymer microspheres release the drug when injected in vivo.

9. The porous polymer microspheres according to claim 5, wherein the drug for treating soft tissue diseases is kartogenin, ibuprofen, curcumin or a mixture thereof.

10. A method for manufacturing porous polymer microspheres for preventing or treating soft tissue diseases comprising:

1) dissolving a biocompatible polymer and a drug for treating soft tissue diseases in an organic solvent to prepare a polymer solution;

2) homogenizing the polymer solution and an aqueous gelatin solution to prepare an emulsion;

3) pouring the emulsion as a discontinuous phase and a polyvinyl alcohol solution as a continuous phase into a fluidic device to produce polymer microspheres including the biocompatible polymer, the drug and gelatin; and

4) stirring the polymer microspheres in 38-50°

C. water to release the gelatin from the polymer microspheres.

11. The method according to claim 10, wherein the drug is incorporated in an amount of 2 to 30 parts by weight with respect to 10 parts by weight of the biocompatible polymer.

12. The method according to claim 10, wherein in homogenization, 3 to 15 parts by weight of the gelatin is added with respect to 10 parts by weight of the biocompatible polymer.

13. The method according to claim 10, wherein the biocompatible polymer is selected from the group consisting of:

any one selected from polyglycolic acid (PGA), polylactic acid (PLA), poly(lactide-co-glycolide) (PLGA), polycaprolactone (PCL), polyamino acid, polylactide, polyphosphazine, polyiminocarbonate, polyphosphoester, polyanhydride, polyorthoester, polyhydroxyvalerate, polyhydroxybutyrate, hyaluronic acid, cellulose, heparin, collagen, alginate and chitosan;

polymers blended with two or more thereof; and

copolymers of two or more thereof.

14. The method according to claim 10, wherein, in step 2), 0.5 to 3 parts by weight of an emulsion stabilizer is further added.

15. The method according to claim 10, wherein the porous polymer microspheres have a porosity of 10 to 90%, a pore size of 5 to 100 μ

m and a particle size of 200 to 1,000 μ

m.

16. The method according to claim 10, wherein the porous polymer microspheres have a porosity of 60 to 90%, a pore size of 10 to 40 μ

m and a particle size of 100 to 400 μ

m.

17. The method according to claim 10, wherein the soft tissue disease is selected from Achilles tendinitis, rotator cuff tendinitis, patellar tendinitis, sprains, ligamentitis, degenerative osteoarthritis and inflammatory arthritis.

18. The method according to claim 10, wherein, in step 2), homogenization is carried out using a homogenizer at 8,000 to 20,000 rpm for 30 seconds to 10 minutes.

19. The method according to claim 10, wherein a release amount and rate of the drug are regulated by controlling a content of the gelatin and/or the drug with respect to a content of the biocompatible polymer.

20. The method according to claim 10, wherein the aqueous gelatin solution is a 1 to 10 wt % aqueous gelatin solution.

21. The method according to claim 10, wherein the discontinuous phase and the continuous phase are each poured at a flow rate of 0.2 to 1 mL/min.

22. The method according to claim 10, wherein the organic solvent comprises one or more selected from dimethylsulfoxide, dichloromethane, tetrahydrofuran and N,N-dimethylformamide.

23. The method according to claim 10, wherein the drug for treating soft tissue diseases is selected from transforming growth factor (TGF), platelet derived growth factor (PDGF), basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), insulin like growth factor (IGF), bone morphogenetic protein-7 (BMP-7), anti-inflammatory peptide, aspirin, mefenamic acid, diclofenac sodium, indomethacin, naproxen, acetaminophen, ketoprofen, loxoprofen, piroxicam, ibuprofen, simvastatin, atorvastatin, fluvastatin, lovastatin, copper-peptide, prostaglandin, tramadol, celecoxib, glucosamine, chondroitin, diacerein, methotrexate, cyclosporine, a Janus Kinase 3 inhibitor (JAK-3 inhibitor), rituximab, tocilizumab, salazosulfapyridine (SASP), bucillamine, leflunomide, infliximab, etanercept, adalimumab, prednisolone, antiflammin 2, curcumin, sulfasalazine, lactoferrin and kartogenin, ibuprofen or a mixture thereof.